Integrated Biomarker Imaging Study 2 was a one year, 300 participant, international, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of darapladib in subjects with angiographically documented coronary heart disease. The study's main objectives were to determine the effects of darapladib on composition and biomechanical properties of atherosclerotic plaque, as well as circulating inflammatory biomarkers. Glaxo Smith Kline was the sponsor of the study. Volcanos grayscale IVUS and VH® IVUS derived key vessel volumes and measurements from baseline and at one year follow up. Results of this study were presented on September 2, 2008 at the European Society of Cardiologists (ESC) in Munich, Germany.
Volcano's VH IVUS technology uses advanced spectral analysis techniques to allow simplified interpretation of ultrasound images and provide detailed information on the composition of each patient's atherosclerotic plaques. The colorized VH images show four plaque component types: fibrous, fibro-fatty, dense calcium, and necrotic core. VH IVUS images are created using Volcano's imaging systems along with the Eagle Eye® Gold IVUS imaging catheter.